[Raynaud's phenomenon: effects of terazosin].
After considering the clinical and physiopathological aspects of Raynaud's phenomenon, the authors have evaluated the medium effects of therazosine in 2 groups of patients, respectively with idiopathic and secondary Raynaud's phenomenon. The results show that the therazosin determines a decrease of number, intensity and duration of vasospastic attacks to the hands as well as an improvement of telethermographic and ultrasonographic findings.
Paterna
S
S
Istituto di Patologia Medica, Università degli Studi, Palermo.
Pinto
A
A
Arrostuto
A
A
Cannavò
M G
MG
Di Pasquale
P
P
Cottone
C
C
Licata
G
G
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011928:Raynaud Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014463:Ultrasonography
D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin